8-K: Quanterix Announces Q4 2024 Financial Results and Akoya Biosciences Acquisition

Quanterix reports 11% revenue growth for Q4 2024 and announces a definitive merger agreement to acquire Akoya Biosciences in an all-stock transaction.

Summary

• Quanterix Corporation announced its financial results for the fourth quarter ended December 31, 2024.
• The company reported revenue of $35.2 million for the quarter, an 11% increase compared to $31.5 million in the prior year.
• GAAP gross margin was 63.0%, compared to 61.5% in the prior year, while adjusted gross margin (non-GAAP) was 57.7% compared to 54.7% in the prior year.
• Net loss for the quarter was $11.6 million, compared to a net loss of $8.8 million in the prior year.
• Net cash usage during the quarter was $4.4 million, compared to $6.4 million in the prior year.
• The company ended 2024 with $291.7 million in cash, cash equivalents, marketable securities, and restricted cash.
• Full year 2024 revenue was $137.4 million, a 12% increase compared to $122.4 million in the prior year.
• The company expects 2025 revenue to be in the range of $140.0 million to $146.0 million, representing growth of 2% to 6% over 2024.
• The company anticipates 2025 cash usage to be approximately $55.0 million to $65.0 million, including $20.0 million of upfront payments for the EMISSION acquisition.
• Quanterix announced a definitive merger agreement to acquire Akoya Biosciences in an all-stock transaction, expected to close in the second quarter of 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company achieved revenue growth and is making strategic acquisitions, the increased net loss and lower revenue growth forecast for 2025 temper the overall outlook.

Positives

• Quanterix delivered its seventh consecutive quarter of double-digit revenue growth.
• The company's gross margin improved in Q4 2024.
• The acquisition of Akoya Biosciences is expected to create a leading integrated solution for biomarker detection.
• The launch of Simoa ONE is expected to enhance the company's technology platform.
• The acquisition of EMISSION secures the supply chain for key components.
• The company made significant progress in building global infrastructure for Alzheimer's disease testing.

Negatives

• The net loss increased to $11.6 million in Q4 2024, compared to $8.8 million in the prior year.
• Net cash usage increased for the full year 2024 compared to the prior year.
• The company's revenue growth forecast for 2025 is lower than the growth achieved in 2024.

Risks

• The company's estimates regarding expenses, future revenues, capital requirements, and needs for additional financing could be incorrect.
• There are risks related to the restatement of Quanterixs consolidated financial statements, including risks of increased costs and the increased possibility of legal proceedings and regulatory inquiries, sanctions, or investigation.
• The company faces risks related to its ability to maintain effective internal control over financial reporting and disclosure controls and procedures.
• The company's ability to realize the intended benefits of its assay redevelopment program is uncertain.
• The company's ability to retain and expand its customer base and achieve sufficient market acceptance of its products is not guaranteed.
• The merger with Akoya Biosciences is subject to risks, including the failure to obtain necessary stockholder approvals or to satisfy other conditions, and the possibility that the anticipated benefits and synergies are not realized.

Future Outlook

Quanterix expects 2025 revenue to be in the range of $140.0 million to $146.0 million, representing growth of 2% to 6% over 2024, and anticipates 2025 cash usage to be approximately $55.0 million to $65.0 million.

Management Comments

• Masoud Toloue, Chief Executive Officer of Quanterix, stated that the company delivered 11% revenue growth in Q4, its seventh straight quarter of double-digit growth, despite a capital constrained environment.
• He attributed the company's growth to investments in its business model, which focuses on key vertical markets and recurring revenues.
• He also noted that the acquisition of Akoya Biosciences is an important step forward in the execution of the company's strategy to expand its approach to immunology and oncology.

Industry Context

The acquisition of Akoya Biosciences positions Quanterix to capitalize on the growing market for biomarker detection and clinical tests, particularly in the fields of immunology and oncology. The combination of Quanterix's ultra-sensitive blood-based biomarker detection technology with Akoya's tissue-based protein biomarker analysis capabilities creates a comprehensive solution for researchers and clinicians.

Comparison to Industry Standards

• Quanterix's revenue growth of 11% in Q4 2024 is comparable to other companies in the life sciences and diagnostics industry, such as Bio-Techne, which reported 10% organic growth in its most recent quarter.
• The company's gross margin of 63.0% is also in line with industry averages for diagnostics companies.
• The acquisition of Akoya Biosciences is similar to other recent mergers and acquisitions in the life sciences industry, such as Danaher's acquisition of Abcam, which aim to expand product portfolios and market reach.

Stakeholder Impact

• Shareholders will be impacted by the merger with Akoya Biosciences and the potential dilution from the issuance of new shares.
• Employees of both Quanterix and Akoya may experience changes as a result of the integration of the two companies.
• Customers will benefit from the expanded product portfolio and integrated solutions offered by the combined company.
• Suppliers may be affected by changes in procurement and supply chain management as a result of the merger.
• Creditors may be impacted by changes in the company's financial performance and capital structure.

Next Steps

• Quanterix and Akoya will seek stockholder approval for the merger.
• The companies will work to satisfy the closing conditions for the merger, including regulatory approvals.
• Quanterix plans to launch Simoa ONE by the end of 2025.
• Quanterix will continue to integrate EMISSION into its operations.

Key Dates